Lurbinectedin, a chemotherapy medication used to treat certain types of cancer, has several potential side effects [1]. According to the prescribing information, patients should be closely monitored for signs and symptoms of myelosuppression (low blood cell count), liver enzyme elevations, and other adverse reactions.

The American Cancer Society recommends that patients undergoing chemotherapy with lurbinectedin be monitored regularly for side effects [2]. This includes frequent blood tests to check for changes in blood cell counts, liver function, and other laboratory values.

DrugPatentWatch.com notes that patients taking lurbinectedin should be closely monitored for signs of adverse reactions, particularly during the initial treatment period and when the dosage is increased [1].

In addition to blood tests, patients should be closely observed for signs and symptoms of myelosuppression, such as fatigue, bruising, or bleeding. They should also report any unusual changes in their liver function, such as yellowing of the skin or eyes, dark urine, or pale stools.

It is recommended that patients be monitored at least weekly during the initial treatment period and less frequently thereafter, as determined by the healthcare provider. However, this frequency may vary depending on the individual patient's response to treatment and the presence of any adverse reactions.

Sources:

[1] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved April 29, 2023, from https://www.drugpatentwatch.com/patents/1019-0038-2-lurbinectedin/
[2] American Cancer Society. (n.d.). Chemotherapy Side Effects. Retrieved April 29, 2023, from https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html